## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($177.81)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?**
- Source: Markets Financial Content | 20251215T080700 | Neutral | Relevance: 100%
- Quest Diagnostics (DGX) has seen mixed performance compared to the healthcare sector and competitors. While it lagged the State Street Health Care Select Sector SPDR ETF (XLV) over short and medium terms, DGX outperformed over the past 52 weeks. The company reported strong Q3 2025 results, exceeding analyst expectations for revenue and EPS, and raised its fiscal 2025 guidance.

**2. Bellevue Group AG Makes New $8.72 Million Investment in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251213T093035 | Somewhat-Bullish | Relevance: 100%
- Bellevue Group AG has acquired a new stake of 48,567 shares in Quest Diagnostics Incorporated, valued at approximately $8.72 million. This investment comes as other institutional investors have also adjusted their positions in DGX, and the company has received a "Moderate Buy" consensus rating from analysts with an average price target of $197.27. Quest Diagnostics recently announced a quarterly dividend of $0.80 per share to be paid on January 28th.

**3. Nonalcoholic Steatohepatitis Diagnostics Market Is Going to Boom |• Exact Sciences Corporation • Genfit SA**
- Source: openPR.com | 20251215T080932 | Somewhat-Bullish | Relevance: 83%
- Worldwide Market Reports (WMR) projects substantial growth for the Nonalcoholic Steatohepatitis Diagnostics Market, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report identifies key players such as Exact Sciences Corporation and Genfit SA and segments the market by types and applications. It provides actionable intelligence and forecasts using extensive primary and secondary research.

**4. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Barchart.com | 20251216T124258 | Somewhat-Bullish | Relevance: 73%
- Bio-Techne Corporation (TECH), a mid-cap life sciences company, has underperformed the Health Care Select Sector SPDR Fund (XLV) year-to-date and over the past 52 weeks, despite a recent three-month gain. The company's Q1 2026 revenue declined due to headwinds in cell therapy timing and biotech funding softness. Despite its recent struggles, analysts maintain a "Strong Buy" rating for TECH with a significant upside to its mean price target.

**5. Labcorp (LH): Reassessing Valuation After Reduced Growth Outlook for Contract Research Unit**
- Source: Simply Wall Street | 20251213T185008 | Neutral | Relevance: 64%
- Labcorp Holdings (LH) recently surpassed earnings expectations but saw its stock react negatively due to management's cautious outlook, including reduced revenue growth targets for its contract research unit and a trimmed full-year forecast. Despite a strong 5-year shareholder return, the stock's recent weakness suggests investors are reassessing growth risks. Analysts currently see Labcorp as undervalued with a fair value of $299.71, though its P/E ratio is higher than the broader US healthcare sector.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +6.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 17.7x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.6B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 17.7 |
| Current P/E | 18.8 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.6% to 2.9% (+6.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 3.0% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). RSI neutral at 51. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.85% (CS: 60) | Neutral |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -0.45 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.040x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $184.11
- **Stop Loss:** $177.81 (3.4% risk)
- **Target:** $190.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 190
- **Position Value:** $34,980.90
- **Portfolio %:** 34.98%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*